Reach Us +1-217-403-9671
The Flexibilities For The Regulatory Guidelines For The Bio-similars In Emerging Markets | 33399
ISSN: 2167-7689

Pharmaceutical Regulatory Affairs: Open Access
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

The flexibilities for the regulatory guidelines for the bio-similars in emerging markets

5th International Conference and Exhibition on Pharmaceutical Regulatory Affairs

Poongothai Ramaswamy

Hasan and Singh, India

Posters-Accepted Abstracts: Pharmaceut Reg Affairs

DOI: 10.4172/2167-7689.S1.019

The Regulatory guidelines running parallel to the Intellectual Property Rights (IPR) are the keystones in establishing a well-set ruling system to be adhered to when developing bio-similars either during or after the expiry of the patents of the innovator drugs. As the biologic drugs are developed for most of the life saving drugs, it becomes mandatory that the set guidelines are well adhered to by the similar biologics for proper manifestation and to be on par with the biologics which are highly complex drugs. There is an ever growing health concern for some of the highly dreaded diseases, especially the infectious ones, which tend to progress to malignant stage, like in the case of Human Papilloma Virus, if left without proper diagnosis followed by treatment. As drugs, vaccines and antibodies are being developed or are already developed, the need of the hour is affordability, accessibility and awareness in the emerging markets like India. The operational hurdles for the development of the bio-similars in the emerging markets’ needs, flexibilities and relaxation in the complexities involved in the manufacturing process. It also seeks the immediate attention for the global harmonization from the various international bodies of the highly regulated markets. The introduction of the bio-therapeutics for the betterment of the mankind through its flexibilities in the regulatory norms with special focus to the developing world would go a long way in combating many diseases.

Poongothai Ramaswamy is currently working as a Patent Associate with Hasan and Singh, Hyderabad, India. She carries over 14 years of professional experience, which includes both academia and industry. Her academic qualification includes, Master’s in Human Genetics from Andhra University, Visakapatanam, India and Doctoral degree in Cancer Genetics, pertaining to hematological malignancies, with special emphasis to chronic myeloid leukemia. She is a recipient of UICC, ICRETT Fellowship to carry out part of her PhD work at Institute of Molecular Medicine, Sir John Radcliff Hospital, IMM, OXFORD, UK, under the mentorship of Dr Lyndal Kearney and also a recipient of CSIR and ICMR Fellowships for Post-doctoral Research at Osmania University and Centre for DNA Finger Printing and Diagnostics (CDFD). She also holds a PG diploma in Patent law from NALSAR, Hyderabad, India.

Email: [email protected]